Cen Xu

US Patent:

20130071410, Mar 21, 2013

Filed:

Sep 12, 2012

Appl. No.:

13/612615

Inventors:

Thomas C. Boone - Newbury Park CA, US
David W. Brankow - Northridge CA, US
Chadwick T. King - Vancouver, CA
Hsieng Sen Lu - Westlake Village CA, US
Licheng Shi - Newbury Park CA, US
Cen Xu - Newbury Park CA, US

International Classification:

A61K 39/395
C12N 15/13
C07H 21/04
A61P 25/00
C12P 21/02
C12N 15/63
C12N 1/21
C12N 1/19
C12N 5/10
C07K 16/28
A61P 25/06

US Classification:

4241721, 5303891, 5303879, 5303873, 536 2353, 53038822, 4353201, 43525233, 4352542, 435331, 435 696

Abstract:

Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related, disorders including the treatment and/or prevention of migraine headaches.

US Patent:

20100172895, Jul 8, 2010

Filed:

Dec 18, 2009

Appl. No.:

12/642711

Inventors:

Thomas C. Boone - Newbury Park CA, US
David W. Brankow - Northridge CA, US
Chadwick T. King - N. Vancouver, CA
Hsieng Sen Lu - Westlake Village CA, US
Licheng Shi - Newbury Park CA, US
Cen Xu - Newbury Park CA, US

International Classification:

A61K 39/395
C12P 21/00
C12N 5/10
C12N 5/00
C07K 2/00
C07K 16/00
C07H 21/04

US Classification:

4241301, 435 696, 435325, 435358, 435364, 435366, 4353201, 530300, 5303871, 5303873, 5303881, 536 2353

Abstract:

Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.

US Patent:

20220195022, Jun 23, 2022

Filed:

Dec 21, 2021

Appl. No.:

17/558032

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Los Altos CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
C07K 16/28
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

US Patent:

20210095016, Apr 1, 2021

Filed:

Sep 24, 2020

Appl. No.:

17/031674

Inventors:

- Thousand Oaks CA, US
Cen XU - Newbury Park CA, US
Hong SUN - Belmont MA, US
Yuan D. SHIH - Calabasas CA, US
Dohan WEERARATNE - Ventura CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/26
A61P 25/06
C07K 16/42

Abstract:

The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

US Patent:

20210047422, Feb 18, 2021

Filed:

Aug 27, 2020

Appl. No.:

17/005202

Inventors:

- Thousand Oaks CA, US
Ling LIU - Thousand Oaks CA, US
Edward J. BELOUSKI - Thousand Oaks CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28
C07K 16/18

Abstract:

The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.

US Patent:

20210017261, Jan 21, 2021

Filed:

Jul 1, 2020

Appl. No.:

16/919032

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Palo Alto CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
C07K 16/28
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

US Patent:

20190218279, Jul 18, 2019

Filed:

Jan 11, 2019

Appl. No.:

16/246326

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Palo Alto CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

US Patent:

20180362643, Dec 20, 2018

Filed:

Dec 15, 2016

Appl. No.:

16/063152

Inventors:

- Thousand Oaks CA, US
Cen XU - Newbury Park CA, US
Hong SUN - Belmont MA, US
Yuan D. SHIH - Calabasas CA, US
Dohan WEERARATNE - Ventura CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/26
C07K 16/42
A61P 25/06

Abstract:

The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.